In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma Quarterly Dealmaking Statistics, Q2 2018

A look at financing, M&A and alliance activity April–June 2018

Executive Summary

Biopharma financing for the second quarter totaled $12.4 billion, a 25% decrease from Q1 2018. Meanwhile Q2 merger and acquisition deal value reached $101 billion, three-quarters of which came from Takeda's $79 billion takeover of major European player Shire. Alliances – totaling $13.8 billion (a significant decline from the previous quarter's $30.7 billion) – featured large partnerships in the antibody space, the biotechnology industry sector with the highest dollar volume.

Advertisement

Related Content

Brii Bio: Partnering To Bring Innovation To China
BI’s Business Development Focus Remains On Early Collaboration
Lilly Reacquires Aurora Kinase Inhibitor Via AurKa Buy For $110m
$1.6bn ARMO Buy Gives Lilly Its Most Advanced Immuno-Oncology Asset
Takeda Poised To Move Into Pharma Top 10 With Shire Combination
P&G Adds Merck's Brands, Expands Consumer Health Categories, Footprint
Sanofi's Generics Business To Be Sold To Private Equity Firm, Advent
Servier Acquires Shire Oncology Business For $2.4bn
Novartis Goes Big On Gene Therapy With $8.7bn AveXis Acquisition
'We Jumped' At Opportunity To Take On Pfizer's CAR-T Program, Allogene's Chang Says

Topics

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV123549

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel